6808.TWO 3D Global Biotech Inc.
- Market cap
- TWD 2.04B
- P/E
- 147.5x
- P/B
- 2.90x
- ROE
- 6.8%
- Dividend yield
- 2.02%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6808.TWO undervalued?
Graham numberThe Graham number of 3D Global Biotech Inc. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
3D Global Biotech Inc. fundamental analysis
No fundamental analysis for 3D Global Biotech Inc. yet.
3D Global Biotech Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About 3D Global Biotech Inc.
3D Global Biotech Inc. manufactures and sells medical devices for human body reconstruction. It offers artificial bone grafting; 3D bioForming; bio-dressing; 3D bioture EX; 3D printing equipment, such as 3D BioRealizer system; orthodontic aligner system under the SmileAlign name; and iMatrix, a sectional matrix kit. The company was founded in 2014 and is based in New Taipei City, Taiwan.
Full company profile3D Global Biotech Inc. financial statements
3D Global Biotech Inc. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 18.2M | 13.3M | 11.1M | 13.6M | 20.6M | 266M | 207M |
| Gross Profit | 7.92M | 4.97M | 1.80M | 2.72M | 5.27M | 175M | 148M |
| Operating Income | -36.3M | -50.3M | -62.2M | -66.3M | -62.9M | 88.7M | 44.2M |
| EBITDA | -22.4M | -24.0M | -35.8M | -57.0M | -35.8M | 118M | 81.4M |
| Net Income | -36.3M | -47.9M | -59.7M | -67.1M | -58.0M | 91.7M | 66.5M |
| EPS | -0.72 | -0.89 | -1.11 | -1.22 | -1.03 | 1.30 | 0.86 |
| Balance Sheet | |||||||
| Total Assets | 506M | 483M | 425M | 371M | 324M | 1.04B | 1.09B |
| Total Liabilities | 6.38M | 33.8M | 34.8M | 30.7M | 30.7M | 133M | 106M |
| Shareholders' Equity | 489M | 449M | 390M | 341M | 293M | 905M | 985M |
| Cash & Short-term Investments | 297M | 277M | 233M | 208M | 166M | 704M | 17.4M |
| Total Debt | 7.53M | 20.8M | 21.3M | 16.8M | 10.4M | 84.8M | - |
| Cash Flow | |||||||
| Operating Cash Flow | -17.6M | -23.2M | -36.0M | -34.5M | -31.6M | 19.7M | 111M |
| Capital Expenditure | 35.0K | 30.0K | 2.89M | 856K | 778K | 4.91M | 6.31M |
| Free Cash Flow | -17.7M | -23.3M | -38.9M | -35.3M | -32.4M | 14.7M | 105M |
| Ratios | |||||||
| ROE | -7.4% | -10.7% | -15.3% | -19.7% | -19.7% | 10.1% | 6.8% |
| ROA | -7.2% | -9.9% | -14.1% | -18.1% | -17.9% | 8.8% | 6.1% |
| Net Profit Margin | -199.8% | -361.3% | -539.1% | -491.7% | -280.9% | 34.5% | 32.2% |
| Debt to Equity | 0.02x | 0.05x | 0.05x | 0.05x | 0.04x | 0.09x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
3D Global Biotech Inc. dividends
- Dividend yield
- 2.02%
- Forward dividend
- 0.13 TWD
- Payout ratio
- 62.0%
- Ex-dividend date
- Jul 16, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 41.3M | 0.54 | 62.0% |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns 3D Global Biotech Inc.
Ownership data of 3D Global Biotech Inc. is not available yet.
3D Global Biotech Inc. company profile
- Company name
- 3D Global Biotech Inc.
- Ticker
- 6808.TWO
- ISIN
- TW0006808009
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 43
- Fiscal year end
- December
- Address
- No.99, Xintai 5th Road, New Taipei City, Taiwan, 221
- Phone
- 886 2 2697 1270
- Website
- 3dglobalbiotech.com.tw
About 3D Global Biotech Inc.
3D Global Biotech Inc. manufactures and sells medical devices for human body reconstruction. It offers artificial bone grafting; 3D bioForming; bio-dressing; 3D bioture EX; 3D printing equipment, such as 3D BioRealizer system; orthodontic aligner system under the SmileAlign name; and iMatrix, a sectional matrix kit. The company was founded in 2014 and is based in New Taipei City, Taiwan.
3D Global Biotech Inc. management
3- Mr. Keng-Liang OuChairman & GM
- Rui Wen HuangDeputy General Manager of Finance Department & Accounting Supervisor
- Xu An PanChief of R&D